By Dr Abhi Pal

Journal articles

Saleh Moussa R; Edwards LM; Camit M; Jeyachandran C; Luckett T; Smith B; Brady B; Kochovska S; Bejjani C; Gonzalez M; El-Kabbout N; Abousamra A; Gadalla A; Zakhary I; Matti A; Kattan R; Wu V; Chua W; Wong K; Subramaniam S; McErlean G; Sidhu B; Jennings M; Avery S; Karikios D; Boyle F; Trad W; Ng W; Della-Fiorentina S; Hong M; Nindra U; Fielding S; Agar M; Pal A, 2026, 'Healthcare professionals’ perspectives on the barriers and enablers of cancer clinical trial participation among Arabic-speaking cancer patients in Australia: a qualitative study', Trials, 27, http://dx.doi.org/10.1186/s13063-026-09815-z

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance', Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 32, pp. 3991 - 4000, http://dx.doi.org/10.1158/1078-0432.CCR-26-0733

Liu J; Farrow M; Hsing S; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson A; Park JJ; Rodrigues A; Chan W; Wei J; Cohen J; Underhill C; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study', Clinical Cancer Research, 32, pp. a056 - a056, http://dx.doi.org/10.1158/1557-3265.d32026-a056

Nguyen J; Nindra U; Tang J; Zwieky W; Hong JH; Hong M; Descallar J; Killen A; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2026, 'Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials', Cancers, 18, http://dx.doi.org/10.3390/cancers18081242

Ding P; Jasas K; Bray V; Pal A; Moor R, 2026, 'Real-World Treatment and Outcomes in Resectable Early-Stage Non-Small Cell Cancer: THASSOS-INTL Australia Cohort', Aging Medicine, 9, pp. 137 - 147, http://dx.doi.org/10.1002/agm2.70077

Li JJ; Saab J; Bray V; Williamson J; Pal A; Yip PY; Ding P; Vinod SK; French B; Lee C; Gupta R; Cooper WA; Wang B; Lee CS, 2026, 'Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series', Pathology, 58, pp. 41 - 51, http://dx.doi.org/10.1016/j.pathol.2025.07.009

Nguyen J; Battisti NML; Ní Chróinín D; Hong M; Nindra U; Hong JH; Zwieky W; Wilkinson K; Yoon R; Cooper A; Roohullah A; Ng W; Chua W; Pal A, 2025, 'Inclusion of Older Adults in Early-Phase Cancer Clinical Trials: Safety, Efficacy and a Way Forward', Drugs and Aging, 42, pp. 1143 - 1158, http://dx.doi.org/10.1007/s40266-025-01260-y

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf108

Huang N; Descallar J; Vo S; Lee SS; Wilkinson K; Roohullah A; Cooper A; Bray V; Chua W; Ní Chróinín D; Pal A, 2025, 'Documentation of Advance Care Planning in Early Phase Cancer Clinical Trials: An Australian Single-Centre Experience', Cancers, 17, http://dx.doi.org/10.3390/cancers17223655

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study', JCO Oncology Practice, 3, pp. 1 - 1, http://dx.doi.org/10.1200/OP-25-00412

Young AL; McEnallay M; Day F; Vinod SK; Stone E; Morris S; Stefanovska E; Devitt B; Yip PY; Kukard C; Pal A; Thawal V; Wright G; Hofman A; Sareen H; McLennan J; Wong SO; Rubio C; Liu J; Smith A; Betts D; Mack J; Donnelly J; Barker D; Paul C, 2025, 'A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking', Asia Pacific Journal of Clinical Oncology, 21, pp. 368 - 376, http://dx.doi.org/10.1111/ajco.14153

Grant SJ; Ouriques M; Pal A; Lee S; Challam S; Jasicki L, 2025, 'Improving Ethnic Diversity in Cancer Trials Through Healthcare Interpreter Training', Cancer Medicine, 14, http://dx.doi.org/10.1002/cam4.71071

Young AL; McEnallay M; Day F; Vinod SK; Stone E; Morris S; Stefanovska E; Devitt B; Yip PY; Kukard C; Pal A; Thawal V; Wright G; Hofman A; Sareen H; McLennan J; Wong SO; Rubio C; Liu J; Smith A; Betts D; Mack J; Donnelly J; Paul C, 2025, 'Smoking Cessation Practices in Australian Oncology Settings: A Cross-Sectional Study of Who, How, and When', Asia Pacific Journal of Clinical Oncology, 21, pp. 290 - 299, http://dx.doi.org/10.1111/ajco.14148

Nindra U; Tang J; Hong JH; Hong M; Teng C; Wei J; Killen A; Cooper A; Wilkinson K; Ng W; Lemech C; Chua W; Pal A, 2025, 'Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf035

Shahnam A; Davis A; Brown LJ; Sullivan I; Lin K; Ng C; Yeo N; Kong BY; Khoo T; Warburton L; Da Silva IP; Mullally W; Xu W; O'Byrne K; Bray V; Pal A; Mersaides A; Itchins M; Arulananda S; Nagrial A; Kao S; Alexander M; Lee CK; Solomon B; John T, 2025, 'Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations', Lung Cancer, 201, http://dx.doi.org/10.1016/j.lungcan.2025.108421

Childs S; Nindra U; Shivasabesan G; Yoon R; Haider S; Hong M; Cooper A; Roohullah A; Wilkinson K; Chua W; Pal A, 2025, 'Social Characteristics of Culturally and Linguistically Diverse Cancer Patients Enrolled in Early Phase Clinical Trials in South Western Sydney', Oncology Switzerland, 103, pp. 219 - 226, http://dx.doi.org/10.1159/000540462

Xue J; Lugowska I; Simonelli M; Sacher AG; Stathis A; Dziadziuszko R; Park JO; Garcia VM; Yeh Y-M; Sendur MAN; Su Y-L; Caglevic C; Xu R-H; Perets R; Ahern ES; Pal A; Jemielita T; Molife RL; Choi SY; Rojas CI, 2025, '198MO MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001', Annals of Oncology, 36, pp. s1822 - s1823, http://dx.doi.org/10.1016/j.annonc.2025.10.021

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, '991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', Annals of Oncology, 36, pp. s649, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.', Journal of Clinical Oncology, 43, pp. 11119 - 11119, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11119

Nguyen JTT; Nindra U; Tang J; Hong JH; Zwieky W; Hong M; Killen A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech C; Chua W, 2025, 'Measuring what matters: RECIST response does not predict HRQoL in early-phase trials', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1003

Weickhardt AJ; Foroudi F; Lawrentschuk N; Xie J; Ko Y-A; Sidhom M; Pal A; Grimison PS; Zhang AY; Ng S; Tang C; Hovey EJ; Chen C; Hruby G; Guminski AD; Oakes SR; Conduit C; Tran B; Davis ID; Hayne D; Group AANZUAPCT, 2025, 'Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).', Journal of Clinical Oncology, 43, pp. 4577 - 4577, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4577

Nindra U; Hong JH; Tang J; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase clinical trials.', Journal of Clinical Oncology, 43, pp. 11118 - 11118, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11118

Lugowska IA; Simonelli M; Xue J; Sacher AG; Stathis A; Dziadziuszko R; Park JO; Moreno V; Yeh Y-M; Sendur MAN; Su HY-L; Caglevic C; Xu R-H; Perets R; Ahern ES; Pal A; Jemielita T; Molife LR; Choi YS; Rojas C, 2025, 'The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.', Journal of Clinical Oncology, 43, pp. 3508 - 3508, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.3508

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Pal A; Moussa RS; Smith B; Brady B; Karikios D; Boyle F; Chua W, 2024, 'Structural racism and inequity in cancer clinical trial participation: Time for solutions', Jnci Cancer Spectrum, 8, http://dx.doi.org/10.1093/jncics/pkae089

Nindra U; Bray V; Karikios D; Shafiei M; Subramaniam S; Ding P; Kao S; Pal A, 2024, 'Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists', Oncology Switzerland, 102, pp. 732 - 736, http://dx.doi.org/10.1159/000535855

McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A, 2024, 'Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso', Journal of Thoracic Oncology, 19, pp. 636 - 642, http://dx.doi.org/10.1016/j.jtho.2023.11.014

Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W, 2024, 'Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer', Internal Medicine Journal, 54, pp. 596 - 601, http://dx.doi.org/10.1111/imj.16224

Lugowska IA; Rojas C; Stathis A; Weindler S; Pal A; Alvarez EC; Mackiewicz J; Garrido M; Sendur MAN; Lakhani NJ; Frentzas S; Dziadziuszko R; Sacher AG; Wakuda K; Kato T; Perets R; Fernandez OOC; Jemielita T; Choi Y; Juergens RA, 2024, 'A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors', Journal of Clinical Oncology, 42, http://dx.doi.org/10.1200/JCO.2024.42.3_suppl.TPS232

Whitaker KL; Cox A; McErlean G; Pal A; Stansbury K; Estupiñán Fdez De Mesa M; Kerrison RS; Gil N; Marcu A; Armes J; Yap ML; Delaney GP; Hoyo C; Pal A, 2024, 'Integrating Implementation Theory to Address Inequities in Cancer Care: Perspectives from an International Working Group', European Journal of Cancer Care, 2024, http://dx.doi.org/10.1155/2024/9994508

Rojas CI; Lugowska I; Juergens R; Sacher A; Weindler S; Sendur MAN; Dziadziuszko R; Pal A; Alvarez EC; Ahern ES; Lakhani N; Chen L; Jemielita T; Choi SY; Stathis A, 2024, '44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC', ESMO Open, 9, pp. 102273, http://dx.doi.org/10.1016/j.esmoop.2024.102273

Nindra U; Pal A; Lea V; Lim SHS; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Soon Lee C; Chua W, 2023, 'Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population', Plos One, 18, http://dx.doi.org/10.1371/journal.pone.0292087

Pal A; Daly R; Stapleton S; Yap C; Hong M; Grochot R; MohamedKhan S; Lai-Kwon JE; Magkos D; Rao Baikady B; Minchom AR; Banerji U; De Bono JS; Karikios DJ; Boyle FM; Lopez JS, 2023, 'CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials.', Journal of Clinical Oncology, 41, pp. 6560 - 6560, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6560

Nindra U; Pal A; Lee CS, 2023, 'Precision medicine in Australia: now is the time to get it right', Medical Journal of Australia, 218, pp. 330, http://dx.doi.org/10.5694/mja2.51887

Rojas C; Lugowska I; Juergens R; Sacher A; Weindler S; Sendur MAN; Dziadziuszko R; Pal A; Alvarez EC; Ahern ES; Lakhani N; Chen L-C; Jemielita T; Choi YS; Stathis A, 2023, '663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC', Annals of Oncology, 34, pp. s466 - s467, http://dx.doi.org/10.1016/j.annonc.2023.09.1849

Pal A; Daly R; Mohamedkhan S; Grochot R; Stapleton S; Yap C; Magkos D; Baikady BR; Minchom A; Banerji U; De Bono J; Karikios D; Boyle F; Lopez J, 2022, 'CONSENT - A Randomised Controlled Trial of Enhanced Informed Consent Compared to Standard Informed Consent to Improve Patient Understanding of Early Phase Oncology Clinical Trials – GBM Cohort (Nonrandomised) Analysis', Neuro-Oncology, 24, pp. iv14 - iv14, http://dx.doi.org/10.1093/neuonc/noac200.060

Papadatos-Pastos D; Yuan W; Pal A; Crespo M; Ferreira A; Gurel B; Prout T; Ameratunga M; Chénard-Poirier M; Curcean A; Bertan C; Baker C; Miranda S; Masrour N; Chen W; Pereira R; Figueiredo I; Morilla R; Jenkins B; Zachariou A; Riisnaes R; Parmar M; Turner A; Carreira S; Yap C; Brown R; Tunariu N; Banerji U; Lopez J; De Bono J; Minchom A, 2022, 'Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors', Journal for Immunotherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2022-004495

Nindra U; Stevens SX; Shahnam A; Pal A; Adam T; Yip PY; Lee JHJ; Boyer MJ; Nagrial A; Kao SC-H; Bray VJ, 2022, 'The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.', Journal of Clinical Oncology, 40, pp. e18810 - e18810, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18810

Nindra U; Shahnam A; Stevens SX; Pal A; Yip PY; Adam T; Lee JHJ; Boyer MJ; Nagrial A; Kao SC-H; Bray VJ, 2022, 'The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab.', Journal of Clinical Oncology, 40, pp. e18773 - e18773, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18773

Stapleton SE; Darlington AS; Minchom A; Pal A; Raynaud F; Wiseman T, 2022, 'Assessing cognitive toxicity in early phase trials - What are we missing?', Psycho Oncology, 31, pp. 405 - 415, http://dx.doi.org/10.1002/pon.5834

Stevens S; Nindra U; Shahnam A; Bray V; Pal A; Yip PY; Adam T; Nagrial A; Lee JH; Boyer M; Kao SC-H, 2022, '965P Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience', Annals of Oncology, 33, pp. s989, http://dx.doi.org/10.1016/j.annonc.2022.07.1091

Pal A; Shinde R; Miralles MS; Workman P; de Bono J, 2021, 'Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development', Nature Reviews Clinical Oncology, 18, pp. 454 - 467, http://dx.doi.org/10.1038/s41571-021-00489-x

Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS, 2021, 'Targeting the p300/cbp axis in lethal prostate cancer', Cancer Discovery, 11, pp. 1118 - 1137, http://dx.doi.org/10.1158/2159-8290.CD-20-0751

Lai-Kwon J; Tiu C; Pal A; Khurana S; Minchom A, 2021, 'Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective', Critical Reviews in Oncology Hematology, 159, http://dx.doi.org/10.1016/j.critrevonc.2021.103225

Tiu C; Shinde R; Pal A; Biondo A; Lee A; Tunariu N; Jhanji S; Grover V; Tatham K; Gruber P; Banerji U; De Bono JS; Nicholson E; Minchom AR; Lopez JS, 2021, 'A wolf in sheep’s clothing: Systemic immune activation post immunotherapy', Journal of Immunotherapy and Precision Oncology, 4, pp. 189 - 195, http://dx.doi.org/10.36401/JIPO-21-9

Biondo A; Pal A; Riisnaes R; Shinde R; Tiu C; Lockie F; Baker C; Bertan C; Crespo M; Ferreira A; Pereira R; Figueiredo I; Miranda S; Gurel B; Carreira S; Banerji U; de Bono J; Lopez J; Tunariu N; Minchom A, 2021, 'Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience', Cancer Treatment and Research Communications, 27, http://dx.doi.org/10.1016/j.ctarc.2021.100309

van Zyl MD; Clarkson M; Hanwell J; Cooley B; Pal A; Lai-Kwon JE; Stapleton S, 2021, 'CN9 An exploratory qualitative study to describe the experience of using a question prompt list for patients in early phase clinical trials', Annals of Oncology, 32, pp. S1259 - S1259, http://dx.doi.org/10.1016/j.annonc.2021.08.633

Rivalland G; Kao SC-H; Pavlakis N; Hughes BGM; Thapa B; Pal A; Walkiewicz M; Zimet AS; White S; O'Byrne K; Mitchell P; John T, 2017, 'Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.', Journal of Clinical Oncology, 35, pp. 8514 - 8514, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.8514

Back to profile page